06/03/2026
Recently, Dr. Fleener led a journal club discussion on the New England Journal of Medicine article, “Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.” NEJM Study
The study looks at an exciting advancement in the treatment of resectable stage III Melanoma, evaluating immunotherapy given before surgery using a combination of Opdivo and Yervoy.
Research like this continues to show how quickly cancer care is evolving—and how earlier use of immunotherapy may help improve outcomes for patients.
Even more importantly, it highlights what we value as a team. Journal club is one of the ways we come together to stay current, learn from new data, and think critically about how to best care for our patients.
At the heart of it all is collaboration. Physicians, advanced practice providers, pharmacists, nurses, and our entire care team working together to continuously improve the care we provide.
We’re grateful for the opportunity to learn together and keep pushing forward for our patients.
https://www.nejm.org/doi/full/10.1056/NEJMoa2402604
In phase 1–2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. In this phase 3 trial, we randomly assig...